ProPhase Labs Rejects $1.60 Proposal from Matrixx

Loading...
Loading...
ProPhase Labs, Inc.
PRPH
(www.ProPhaseLabs.com) announced today that it has rejected the revised and unsolicited, non-binding proposal from Matrixx Initiatives, Inc. ("Matrixx") to acquire the Company for $1.60 per share in cash. This most recent proposal, like their prior $1.40 per share proposal, is conditioned on further due diligence by Matrixx. Matrixx is the owner of the Zicam(R) brand of cold and allergy products and is a direct competitor to ProPhase's Cold-EEZE(R) Cold Remedy product line.
Posted In: NewsFDAM&A
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...